Skip to content
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — Januar 2025

Genmab — Januar 2025

Planlagt Fastgjort Låst Flyttet Genmab
702 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • S Offline
    S Offline
    Stroka
    wrote on sidst redigeret af
    #427

    God morgen 🙂

    1 Reply Last reply
    0
    • P Offline
      P Offline
      ProinvestorNEWS
      wrote on sidst redigeret af
      #428

      Genmab får sakset 15 pct. af kursmålet hos amerikansk børshus https://proinvestor.com/investornyt/1268962/genmab-far-sakset-15-pct-af-kursmalet-hos-amerikansk-borshus

      1 Reply Last reply
      0
      • M Offline
        M Offline
        mobbyduck1
        wrote on sidst redigeret af
        #429

        det ligner et hak i tuden i dag, desværre....

        1 Reply Last reply
        0
        • J Offline
          J Offline
          JKY_VH
          wrote on sidst redigeret af
          #430

          Ja GS føler åbenbart trang til at lukke en "bæ" ud. Jeg synes ikke umiddelbart at der er nogen forklaring bortset fra usikkerhed omkring Hexa og det er jo ingen nyhed.

          1 Reply Last reply
          0
          • M Offline
            M Offline
            mobbyduck1
            wrote on sidst redigeret af
            #431

            genmab er så billig, at man får alt gratis, hvis man trækker Darzalex og egenkapital fra. Det er helt til grin

            1 Reply Last reply
            0
            • E Offline
              E Offline
              E_L
              wrote on sidst redigeret af
              #432

              New Mount Sinai Trial Reveals Major Advance in Treatment of Aggressive Lymphoma https://www.mountsinai.org/about/newsroom/2025/new-mount-sinai-trial-reveals-major-advance-in-treatment-of-aggressive-lymphoma

              1 Reply Last reply
              0
              • E Offline
                E Offline
                E_L
                wrote on sidst redigeret af
                #433

                Danish biotech Genmab (CPH: GMAB) today announced it has named Leslie Amendola senior vice president and general manager of its US business. https://www.thepharmaletter.com/genmab-names-us-general-manager https://www.linkedin.com/posts/genmab_newsupdate-activity-7288199613231120386-i8xM/

                1 Reply Last reply
                0
                • Helge_LarsenPI-redaktørH Offline
                  Helge_LarsenPI-redaktørH Offline
                  Helge_LarsenPI-redaktør
                  wrote on sidst redigeret af
                  #434

                  Godmorgen 🙂

                  1 Reply Last reply
                  0
                  • E Offline
                    E Offline
                    E_L
                    wrote on sidst redigeret af
                    #435

                    why would Genmab sponsor anything for hemophilia care? https://www.surveymonkey.com/r/H7HFWZ5 (could it have something to do with bleeding side effects from Tisotumab?)( i am assuming it is not related to Hemab, why would it go via Genmab
                    )

                    1 Reply Last reply
                    0
                    • E Offline
                      E Offline
                      E_L
                      wrote on sidst redigeret af
                      #436

                      Brian Slomovitz, MD, MS, FACOG
                      @GynCancerMD

                      Honored to discuss our practice changing study using tisotumab vedotin in patients recurrent cervical cancer. Led to full FDA approval https://x.com/GynCancerMD/status/1882780591390921153 -Podcast

                      1 Reply Last reply
                      0
                      • E Offline
                        E Offline
                        E_L
                        wrote on sidst redigeret af
                        #437

                        Bichoy Gabra, R.Ph., Ph.D.
                        @BichoyGabra
                        Tivdak (tisotumab vedotin-tftv) mechanism of action in metastatic cervical cancer https://x.com/BichoyGabra/status/1881714400291168285

                        1 Reply Last reply
                        0
                        • L Offline
                          L Offline
                          lahn1
                          wrote on sidst redigeret af
                          #438

                          Hmm that interesting noting relevant in the pileline so could be bleeding issue with TV. Did we see any bleeding issues in Rina-s ?

                          1 Reply Last reply
                          0
                          • G Offline
                            G Offline
                            gentogen
                            wrote on sidst redigeret af
                            #439

                            In innovaTV 204, TRAEs of bleeding occurred in 39 patients (39%) and were mostly grades 1 or 2;

                            1 Reply Last reply
                            0
                            • G Offline
                              G Offline
                              gentogen
                              wrote on sidst redigeret af
                              #440

                              Checking your browser - reCAPTCHA

                              favicon

                              (pmc.ncbi.nlm.nih.gov)

                              1 Reply Last reply
                              0
                              • Y Offline
                                Y Offline
                                YPE
                                wrote on sidst redigeret af
                                #441

                                God morgen.. Nogen der kan genopfriske, hvilke taktiske årsager jnj kan have for ikke at tage optionen, hvis data er super gode?

                                1 Reply Last reply
                                0
                                • S Offline
                                  S Offline
                                  Sukkeralf
                                  wrote on sidst redigeret af
                                  #442

                                  De har jo allerede Darzalex FasPro 5 år længere, så de har jo den overvejende indtægt på plads uden at skulle betale royalty til Genmab.

                                  1 Reply Last reply
                                  0
                                  • W Offline
                                    W Offline
                                    w
                                    wrote on sidst redigeret af
                                    #443

                                    Blev faspro patentet ikke underkendt i EU,?

                                    1 Reply Last reply
                                    0
                                    • Y Offline
                                      Y Offline
                                      YPE
                                      wrote on sidst redigeret af
                                      #444

                                      Men hvad med efter 2035? Deres CEO har givet udtryk for at jnj skal være førende indenfor MM og have flere alternativer i alle linjer.

                                      1 Reply Last reply
                                      0
                                      • W Offline
                                        W Offline
                                        w
                                        wrote on sidst redigeret af
                                        #445

                                        hvem ved om gen allerede har afgørelsen og brygger på en pm, forhandler med jj om reduktion af royalty eller forhandler med anden part

                                        1 Reply Last reply
                                        0
                                        • W Offline
                                          W Offline
                                          w
                                          wrote on sidst redigeret af
                                          #446

                                          om anvendelse af hex
                                          i anden indikation

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper